Dutch Court Sides With Teva In Spat Over MS Drug Patent

Law360, New York (October 3, 2013, 4:58 PM EDT) -- A Dutch court has rebuffed a bid by Mylan Laboratories Inc. to have Teva Pharmaceutical Industries Ltd.’s patent for its multiple sclerosis drug Copaxone declared invalid, the latter company announced Thursday.

The District Court in the Hague made the ruling in Mylan’s patent-revocation action, rejecting each of the company’s arguments that Teva’s European Patent 762,888, which covers the relapsing-remitting MS drug, is invalid, according to Teva.

The ruling follows a similar win Israel-based Teva scored in the U.K. High Court of Justice in July, which found the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.